Treatments for COVID-19: Lessons from 2020 and new therapeutic options

Salasc, Fanny; Lahlali, Thomas; Laurent, Emilie; Rosa‐Calatrava, Manuel; Pizzorno, Andrés

doi:10.1016/j.coph.2021.11.002

Cited by 31 publications

(30 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This event could represent a challenge since such infections are often asymptomatic and may pose a risk to vulnerable populations. Consequently, a boost dose could be a possible strategy while awaiting the antiviral [ 22 , 23 ] that could give us a final weapon against SARS-CoV-2. However, considering the highest percentage of asymptomatic patients and the limited data about their capacity to transmit SARS-CoV-2, further screening, quarantine procedures and other prevention strategies should be guaranteed in all vaccinated subjects.…”

Section: Discussionmentioning

confidence: 99%

Risk of SARS-CoV-2 Infection Breakthrough among the Non-Vaccinated and Vaccinated Population in Italy: A Real-World Evidence Study Based on Big Data

Perrella

Bisogno²,

D’Argenzio³

et al. 2022

Healthcare

View full text Add to dashboard Cite

SARS-CoV-2 infection after vaccination can occur because COVID-19 vaccines do not offer 100% protection. The study aim was to assess duration of vaccination coverage, disease symptoms and type of hospitalization among non-vaccinated and vaccinated subjects to evaluate the vaccination trend over time. A retrospective cohort study was carried out among people testing COVID-19 positive in Campania Region using information from the Health Information System of Campania Region (Sinfonia). Vaccination status was assessed considering: no vaccination, partial vaccination and effective vaccination. Univariate and multivariate logistic regression models were constructed to evaluate the association between ICU admissions caused by COVID-19 and gender, age groups and vaccine type. Vaccine coverage duration trends were investigated using segmented linear regression and breakpoint estimations. Vaccination coverage was assessed by analyzing COVID-19 positive subjects in the 9 months after an effective dose vaccination. A significant risk of hospitalization in the ICU was caused by vaccination status: subjects non-vaccinated (OR:7.14) and partially vaccinated (OR:3.68) were 3 and 7 times more at risk of hospitalization, respectively, than subjects effectively vaccinated. Regarding subjects with an effective vaccination, the vaccine’s ability to protect against infection in the months following vaccination decreased. The risk of contracting COVID-19 after vaccination was higher 5 months (β = 1441, p < 0.001) and 7 months (β = 3110, p < 0.001) after administration of an effective dose. COVID-19 vaccines were demonstrated to protect from symptomatic infection by significantly reducing hospitalization risk, and their full protection against SARS-CoV-2 was demonstrated to decrease after 5 months regardless of age, gender or vaccine type.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of SARS-CoV-2 Infection Breakthrough among the Non-Vaccinated and Vaccinated Population in Italy: A Real-World Evidence Study Based on Big Data

Perrella

Bisogno²,

D’Argenzio³

et al. 2022

Healthcare

View full text Add to dashboard Cite

show abstract

“…This event could represent a challenge, since such infections are often asymptomatic and may pose a risk to vulnerable populations. Consequently, a boost dose could be a possible strategy while awaiting the antiviral 18, 19 that could give us a final weapon against SARS-CoV-2. However, considering highest percentage of asymptomatic patients and that few data about their capacity to transmit SARS-CoV-2, further screening, quarantine procedure and other preventing strategies should be guaranteed in all vaccinated subjects.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Infection Breakthrough among the non-vaccinated and vaccinated: a Real World Evidence study based on Big Data

Perrella

BIsogno

D’Argenzio

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: SARS-CoV-2 infection after vaccination can occur because COVID-19 vaccines do not offer 100% protection. The aim of this study was to assess vaccination coverage among people nasopharyngeal swabs, disease symptoms and type of hospitalisation (Intensive Care Unit) between the non-vaccinated and the effective dose vaccinated and to evaluate vaccination trend over time. Methods: A retrospective cohort study was carried out among people tested positive for COVID-19 in Campania Region using collected information from Health Information System of Campania Region (Sinfonia). The status of vaccination was assess according to the following timetable: non-vaccinated; Ineffective dose vaccination; Effective dose vaccination. Univariate and multivariate logistic regression models were conducted to evaluate the association between Intensive Care Unit (ICU) to COVID-19 and gender, age groups and vaccine. To determine vaccine coverage in subjects who received an effective dose, trend changes over time were investigated using segmented linear regression models and breakpoints estimations. Vaccination coverage was assessed by analysing the trend in the percentage of covid 19 positive subjects in the 9 months after vaccination with an effective dose stratified by age group and type of vaccine. Statistical analyses were performed using R platform Results: A significant association with the risk of hospitalisation in Intensive Care Unit was the vaccination status of the subjects: subjects with ineffective dose (adjusted OR: 3.68) and subjects no-vaccination (adjusted OR: 7.14) were at three- and seven-times higher risk of hospitalisation in Intensive Care Unit, respectively, than subjects with an effective dose. Regarding subjects with an effective dose of vaccine, the vaccine's ability to protect against infection in the months following vaccination decreased. The first breakpoints is evident five months after vaccination (β =1.441, p<0.001). This increase was most evident after the seventh month after vaccination (β =3.110, p<0.001). Conclusions: COVID19 vaccines protect from symptomatic infection by significantly reducing the risk of ICU hospitalization for severe disease. However, it seems they have trend to decrease their fully protection against SARS-COV-2 after five months regardless age, sex or type of vaccine. Therefore it seems clear that those not undergoing vaccine had higher risk to develop clinically significant disease and being at risk of ICU stay. Thus, considering highest percentage of asymptomatic patients and that few data about their capacity to transmit SARS-CoV-2, third dose vaccination should be introduced as soon as possible, Finally, a surveillance approach based on the use of integrated BIG Data system to match all clinical conditions too, offer a precise and real analysis with low incidence of errors in the categorization of subjects.

show abstract

“…As of April 22, 2022, about 505 million of cases of the coronavirus disease 2019 (COVID-19) had been confirmed worldwide, causing more than 6 million deaths [ 4 ]. Several treatments have been studied with great speed, from the hype of antibiotics like azithromycin, antimalarials like chloroquine/hydroxychloroquine, and antiparasitics like ivermectin to the well-stablished role of corticosteroids for severe cases and anticoagulants for hospitalized patients [ 5 ]. Antivirals like the orally administered molnupiravir and antibody‐based treatments such as convalescent plasma and the combination of monoclonal antibodies (tocilizumab, anakinra, etc.)…”

Section: Introductionmentioning

confidence: 99%

Characteristics and conflicting recommendations of clinical practice guidelines for COVID-19 management in children: A scoping review

Quincho-Lopez

Chávez-Rimache

Montes-Alvis

et al. 2022

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

Treatments for COVID-19: Lessons from 2020 and new therapeutic options

Cited by 31 publications

References 103 publications

Risk of SARS-CoV-2 Infection Breakthrough among the Non-Vaccinated and Vaccinated Population in Italy: A Real-World Evidence Study Based on Big Data

Risk of SARS-CoV-2 Infection Breakthrough among the Non-Vaccinated and Vaccinated Population in Italy: A Real-World Evidence Study Based on Big Data

SARS-CoV-2 Infection Breakthrough among the non-vaccinated and vaccinated: a Real World Evidence study based on Big Data

Characteristics and conflicting recommendations of clinical practice guidelines for COVID-19 management in children: A scoping review

Contact Info

Product

Resources

About